Innovent Biologics & Spero Therapeutics enter exclusive license for IBI355, a third-generation Fc-silent anti-CD40L antibody

Innovent Biologics, Inc., a leading biopharmaceutical company, and Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced an exclusive license agreement for IBI355 (Spero R&D code:

To access the full article, please log in or subscribe.